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Activation of conventional protein kinase C (PKC)
is critical in the generation of human neutrophil
extracellular traps
Robert D Gray*, Christopher D Lucas, Annie MacKellar, Feng Li, Katia Hiersemenzel, Chris Haslett,
Donald J Davidson† and Adriano G Rossi†
Abstract
Background: Activation of NADPH oxidase is required for neutrophil extracellular trap (NET) formation. Protein
kinase C (PKC) is an upstream mediator of NADPH oxidase activation and thus likely to have a role in NET
formation.
Methods: Pharmacological inhibitors were used to block PKC activity in neutrophils harvested from healthy donor
blood.
Results: Pan PKC inhibition with Ro-31-8220 (p<0.001), conventional PKC inhibition with Go 6976 (p<0.001) and
specific PKCβ inhibition with LY333531 (p<0.01) blocked NET formation in response to PMA. Inhibition of novel and
atypical PKC had no effect. LY333531 blocked NET induction by the diacylglycerol analogue OAG (conventional PKC
activator) (p<0.001).
Conclusions: Conventional PKCs have a prominent role in NET formation. Furthermore PKCβ is the major isoform
implicated in NET formation.
Introduction
Neutrophil granulocytes are key cells of the innate im-
mune system with a primary function of killing invading
microorganisms such as bacteria, fungi and parasites
to prevent pathogenic spread and invasion [1,2]. Once
identified, neutrophils phagocytose and destroy microbes
inside the phagolysosome by localised disgorgement of
granule contents and the generation of reactive oxygen
species (ROS) [3]. Engulfment of the microorganism al-
lows killing to take place in a confined area within the
cell and not in the extracellular space. Neutrophils may
also liberate granule contents and ROS into the sur-
rounding extracellular space to destroy nearby foreign
pathogens. Dysregulation of these processes may cause
histotoxic damage surrounding host cells. More recently a
further extracellular killing mechanism available to neutro-
phils has been described known as neutrophil extracellular
trap (NET) formation [3,4]. NETs are formed by the mi-
xing of cytoplasmic contents with nuclear histones and
DNA to form a network which is propelled to the exterior
of the cell. Microbes are caught in this mesh and killed by
the neutrophil proteins and histones contained in the
NETs. This process of NET formation leads to a form of
cell death, NETosis, that has been characterised as being
different from either apoptosis or necrosis [5].
NET formation is known to be stimulated by specific
cytokines (e.g., interleukin 8 (IL-8)), bacterial products
(e.g., lipopolysaccharide (LPS)) and importantly by clinic-
ally relevant pathogens such as Shigella flexneri, Staphylo-
coccus aureus, Salmonella thyphimurium, Streptococcus
pneumoniae and the fungus Candida albicans [6]. Stimu-
lation and activation of neutrophils with the diacylglycerol
(DAG) mimetic phorbol 12-myristate 13-acetate (PMA)
also results in the production of NETs and has given im-
portant clues as to the possible mechanism involved in
the formation of such structures. It is clear that NET for-
mation following PMA stimulation is dependent on ROS
production (via the NADPH oxidase system) and this is
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likely to follow the activation of protein kinase C (PKC) as
well as other pathways such as raf-MEK-ERK [7].
The PKC isozyme family is comprised of conventional,
novel and atypical isoforms [8]. There are at least four
conventional isozymes: PKCα, PKCβI, PKCβII and PKCγ.
The novel isozyme group has four subtypes: PKCδ, PKCε,
PKCη and PKCθ. The third group, atypical isozymes, con-
sists of PKCζ and PKCι [9]. PMA stimulates conventional
(α, βI, βII, γ) and novel (δ, ε, η, θ) PKC by mimicking the
activating ligand DAG [8]. PKC isoforms of all classifica-
tions have been reported in neutrophils from healthy
donors [10]. Given that PMA activation triggers NET
formation, we hypothesised that specific isoform(s) of
PKC are a key modulator of the NET formation pathway.
To address this hypothesis we evaluated a panel of PKC
inhibitors on NET formation.
Material and methods
Reagents
Dihydrorhodamine (DHR), dimethyl sulfoxide (DMSO),
diphenyliodonium (DPI), Phorbol 12-myristate 13-acetate
(PMA), Ro-31-8220, PKCζ pseudosubstrate myristoyl tri-
fluoroacetate (PKCζ inhibitor) and SYTOX green were
purchased from Sigma-Aldrich (Dorset, UK); Rottlerin,
Gö 6976 and LY333531 were from Calbiochem (Merck)
(Darmstadt, Germany).
Isolation of human neutrophils
Peripheral blood neutrophils were isolated from healthy
human volunteers according to Lothian Research Ethics
Committee approvals #08/S1103/38 via dextran sedi-
mentation and Percoll™ discontinuous gradients as de-
scribed [11,12]. Informed written consent was obtained
from all subjects. Purity of the neutrophils was assessed
by examination of cytocentrifuge preparations and was
greater than 95%.
Assessment of NET formation
Neutrophils (5×104 cells/well) in HBSS containing Ca2+,
Mg2+ and Hepes (20 mM) were aliquoted (180 μl)
into 96 well plates and left to settle for 30 min at
37°C. The inhibitors Ro-31-8220, DPI, rottlerin, PKCζ
inhibitor, Gö 6976 and PKCβ inhibitor were added at
appropriate concentrations to wells in duplicates and
incubated for 30 min before adding PMA. The final
volume in each well was 200 μl. Plates were incubated
for 4 h and then SYTOX green (6 μM final concentra-
tion), a cell-impermeable nucleic acid stain, with an
excitation/emission maxima of 504/523 nm to give a
green fluorescent light, was added and NET formation
was observed by measuring mean fluorescence in 96
well plates. In some experiments 1-oleoyl-2-acetyl-sn-
glycerol (OAG) was used to stimulate cells in place of
PMA. Results were evaluated by measuring the mean
fluorescence in 96 well plates after the subtraction
of background fluorescence. Cells were also visualised
by fluorescent microscopy carried out on a Zeiss
Axiovert S100 fluorescent microscope (Carl Zeiss,
Germany) and an Evos fl inverted microscope (AMG,
Bothwell, WA).
Statistical analysis
Data were assessed by one way ANOVA followed by a
post-hoc Dunnett’s test. The data were expressed as
mean ± standard error of the mean (SEM), and values of
p < 0.05 were considered statistically significant. All sta-
tistics were performed using GraphPad Prism 5 software
(GraphPad, CA, USA).
Results
PMA induced NET formation
Incubation of human neutrophils with PMA induced
dramatic changes in morphology at 4 h after stimulation,
resulting in NETs that stained positive with SYTOX
green which is impermeable to cells with an intact mem-
brane. The abundance of NETs was almost maximal at
10 nM PMA above which the magnitude of NET forma-
tion plateaued (Figure 1A-N). Cells stimulated with
PMA demonstrated typical morphology of diffuse and
spread NETs (Figure 1M). Measuring the level of total
fluorescence with SYTOX green allowed the assessment
of total extracellular DNA and thus NET formation
(Figure 1N). NET formation determined by microscopy
and cell counting (i.e., by expressing the number of areas
of extracellular DNA as a percentage of total cell count
[14]) strongly correlated with the measurement of NET
abundance based on total fluorescence (r2=0.98), data
not shown. Therefore total fluorescence was utilised as
a reliable screening assay in further experiments to
allow a range of inhibitors to be compared, before
confirmation with gold-standard microscopic valid-
ation. This test was reproducible with an average
inter-assay coefficient of variation of 14.3%. As almost
maximal NET formation was gained with 10 nM PMA
(Figure 1B), this concentration was selected for all fur-
ther experiments.
NET formation is PKC and NADPH oxidase dependent
In order to determine whether NET formation was
dependent on the activation of PKC and NADPH oxidase,
cells were preincubated with increasing concentrations of
the specific but isozyme non-selective PKC inhibitor, Ro-
31-8220 or the NADPH inhibitor diphenyloidonium (DPI)
for 30 min and then treated with 10 nM PMA. Both Ro-
31-8220 and DPI, completely inhibited PMA induced
NET formation (Figure 2A and 2B) measured by SYTOX
green fluorescence and confirmed by microscopy. These
data confirm the key role of NADPH oxidase and
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demonstrate that the NET-forming activity of PMA is
critically dependent upon PKC pathways upstream of
NADPH oxidase.
Specific PKC isoforms regulated NET formation
Ro-31-8220 is an inhibitor of multiple PKC isoforms,
therefore in order to investigate PKC isoform specificity,
PKC isoform classes were targeted with specific inhibitors;
Gö 6976 (Conventional), rottlerin (Novel), PKCζ psue-
dosubstrate (Atypical) (Figure 3A, B, C). Figure 3A dem-
onstrates that Gö 6976 significantly inhibited NET
formation at 100 nM (p<0.05) and 1 μM (p<0.001). In con-
trast, Rottlerin and PKCζ psuedosubstrate had no signifi-
cant effect on NET formation (Figure 3B and C). These
Figure 1 PMA induced NET formation: A-M) Cells were treated for 4 h with PMA (A,B: control, C,D: 0.1 nM, E,F 1 nM, G,H 10 nM, I,J
100 nM, K,L 1 μM,) and microscopy performed at a density of 50,000 cells per well in a 96 well plate. Sytox Green cell impermeable dye
was added at a concentration of 6 μM. Cells with a typical morphology of diffuse and spread NETs were noted [in this figure 50,000 cells were
plated in 1 ml of media in plastic 24 well plates and stimulated as above with 100 nM PMA] (M). Scale bars = 10 microns. A greater abundance
of NETs was seen with increases in PMA concentration but abundance was similar in the 10–1000 nM range. N) Fluorescence of extracellular DNA
by cell impermeable Sytox Green was measured with an excitation of 485 nm and measured at 530 nm. Background fluorescence was subtracted
and the abundance of NETS expressed as fluorescence in arbitrary units. The concentration-dependent response of NET formation plateaued after
10 nM PMA. Data show mean +/− SEM for n = 6 independent experiments.
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data were confirmed microscopically and demonstrate a
key role for conventional PKC in NET formation.
PKC β is Primarily Implicated in NET formation in
Response to PMA and OAG
Gö 6976 is an inhibitor of both PKCα and β, thus, in
order to separate the roles of these two isozymes, a spe-
cific PKCβ inhibitor (LY333531) was employed (Figure 4).
LY333531 significantly inhibited NET formation by
PMA at a concentration of 100 nM (p<0.05) and 1 μM
(p<0.01) (Figure 4A). In addition, 1-oleoyl-2-acetyl-sn-
glycerol (OAG; a DAG analogue and activator of con-
ventional PKC isoforms) stimulated NET formation in a
manner similar to that of PMA (albeit at higher
Figure 2 Effect of DPI and Ro-31-8220 on NET formation: Cells
were plated as described and either pre-treated with DPI or
Ro-31-8220 at increasing concentrations, or control media,
before stimulating with PMA at 10 nM for 4 h. NET abundance
was measured by total fluorescence from Sytox Green cell
impermeable dye. A) Pre-treatment with Ro-31-8220 completely
abrogated NET formation at 100 nM and 1 μM. Data show
mean +/− SEM for n=4 independent experiments. *** indicates
p<0.001. B) Pre-treatment with DPI significantly decreased NET
formation at 10 nM, and completely abrogated NET formation at
100 nM and 1 μM. Data show mean +/− SEM for n=4 independent
experiments. *** indicates p<0.001.
Figure 3 Effect of isozyme specific PKC inhibitors on NET
formation: Cells were plated as described and either pre-
treated with at increasing concentrations of Gö 6976
(conventional PKC inhibitor), Rottlerin (atypical PKC inhibitor),
PKCζ psuedosubstrate (novel PKC inhibitor), or control media,
before stimulation with PMA at 10 nM for 4 h. A) Pre-treatment
with Gö 6976 significantly reduced NET formation at 100 nM
(P<0.05) and 1 μM (p<0.001). B) Pre-treatment with Rottlerin had no
effect on NET formation. C) Pre-treatment with PKCζ
psuedosubstrate had no effect on NET formation. Data show mean
+/− SEM for n=3 independent experiments. * indicates p<0.05, ***
indicates p<0.001.
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concentrations) and was also significantly inhibited by
1 μM LY333531 (p<0.01) (Figure 4B). These data were
confirmed by microscopy and delineate a central role for
PKC β in PMA and OAG-induced NET formation
(Figure 4C-J). Interestingly as well as knocking down total
NET production LY333531 completely abrogated the
presence of “spreading NETs” at the 100 nm concentra-
tion but some diffuse NET formation was still observed
(Figure 4K,L).
PKCβ inhibition has downstream effects on oxidative
burst
To elucidate the downstream effects of PKCβ inhibition
we assessed the effects of LY333531 on oxidative burst
as measured by DHR fluorescence on flow cytometry.
LY333531 reduced NADPH oxidative burst at the same
concentrations required to reduce NET formation, with
a partial but significant knock down of activity at
100 nM (p<0.01) and a complete knockdown at 1 μM
Figure 4 Effect of PKC β on NET formation in response to PMA and DAG analogue OAG: Cells were plated as described and
pre-treated with increasing concentrations of LY333531 (PKCβ inhibitor) before treatment with either 10 nM PMA or 20 μM
1-oleoyl-2-acetyl-sn-glycerol (OAG) for 4 h. A) Pre-Treatment with increasing concentrations of LY333531 decreases NET formation in response
to 10 nM PMA. Data show mean +/− SEM for n=6 independent experiments for PMA stimulated cells and n=3 for OAG stimulated cells.
*indicates p<0.05, ***p<0.001. B). Pre-treatment with increasing concentrations of LY333531 completely abrogated NET formation in response to
20 μM OAG. Data show mean +/− SEM for n=3 independent experiments. *** indicates p<0.001. C-J). Pre-treatment with 1 μM LY333531
completely abrogated NET formation in response to PMA and OAG, images representative of n=3 independent experiments (C,D Cells treated
with 10 nM PMA. E,F cells pre-treated with 1 μM LY333531 for 30 min then 10 nM PMA. G,H cells treated with 20 μM OAG. I,G Cells pre-treated
with 1 μM LY333531 for 30 min then 20 μM OAG. K,L Higher magnification images of effects of treatment with 100 nM LY333531 (L) prior to
10 nM PMA. Fluorescent and phase images combined. There is an absence of spreading NET material in the LY333531 treated cells although
some diffuse NET formation is still present at this concentration of inhibitor. Scale bars = 10 microns.
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(p<0.001) in comparison to the positive controls of DPI
and Ro-31-8220 (Figure 5).
Assessment of downstream effects of PKCβ inhibition
with specific inhibitors
ROS generation was assessed by dihydrorhodamine
(DHR) fluorescence as described previously [13]. Neu-
trophils were resuspended in HBSS with cations and
loaded with DHR (2 M; Invitrogen, Carlsbad, CA, USA)
for 10 min. Cells were then incubated with or without
PKCβ inhibitor (at 10, 100 and 1000 nM) or the positive
controls Ro-31-8220 or DPI at 1μM on a shaking heat
block for 30 min before stimulation with PMA 10 nM
for a further 15 min. DHR fluorescence was analyzed by
flow cytometry (FL-1).
Discussion
The results clearly show that NET formation induced by
PMA is PKC and NADPH oxidase dependent. NET
formation was blocked by both Pan-PKC inhibition and
conventional-PKC inhibition. Furthermore, a specific
PKCβ inhibitor (LY333531) also blocked NET formation.
LY333531 has high selectivity for PKCβ over other con-
ventional isoforms (IC50 of around 5 nM) with a 60 fold
selectivity for PKCβ over PKCα [15]. At higher concen-
trations specific inhibitors may have non-selective effects
on other PKC isoforms. The IC50 of LY333531 for PKCα
is around 300 nM, suggesting that the majority of the
effect of this compound at the concentrations utilised in
our study is via the inhibition of PKCβ and not PKCα;
this is evidenced by the significant reduction in NET
formation with 100 nM LY333531. The intracellular
concentration of LY333531 within the neutrophil follow-
ing incubation is unknown but it is unlikely to be fully
absorbed and as such again we would suggest the effects
are due to inhibition of PKCβ. Previous work has dem-
onstrated that PKCβ accounts for 50% of the neutrophil
response to PMA further underlining the likely predom-
inant role of PKCβ in NET production [16].
Oxidative burst and the generation of reactive oxygen
species including superoxide anions (02
-) and nitric oxide
(NO) are fundamental responses of the neutrophil to
inflammatory stimuli and pathogens. NET formation is
dependent on NADPH oxidase activation and conse-
quently on the generation of 02
- which can be blocked by
DPI. DPI inhibits NADPH oxidase by binding to specific
subunits in the enzyme complex and preventing electron
flow and 02
- production [17]. The main component of
NADPH oxidase is the flavocytochrome b558, a dimer of
p22phox and gp91phox, which is an active transporter of
electrons across the membrane. Coupled to these are pro-
teins p40phox, p47phox, p67phox and p21rac which are
crucial to electron translocation [18]. These proteins as-
semble when activated to produce 02
- which are then
spontaneously converted to H2O2. Interestingly, p47phox
has to be phosphorylated to acquire a conformational re-
arrangement to expose the domains that are important for
the NADPH oxidase function, and this phosphorylation is
mediated by PKC [19]. This is consistent with our findings
that PKC is involved in PMA induced NET formation and
furthermore that PKCβ is the isoform crucially involved.
This is further underlined by the finding that oxidative
burst is reduced by concentrations of LY333531 that re-
duce NET formation.
The beneficial anti-microbial effects of NET formation
have been described in several studies [4,20-25]. Indeed,
this is perhaps most pertinently displayed in restoration
of NADPH oxidase function in chronic granulomatous
disease by gene therapy leading to an increased resis-
tance to fungal infection and clinical improvement sec-
ondary to the restoration of the ability to form NETs
[22]. Several studies however have demonstrated a pro-
inflammatory potential of NETs in a diverse range of
diseases including systemic lupus erythematosus [26-28],
cystic fibrosis [1,29,30] and psoriasis [31]. Therefore
the modulation of NET production may be a viable anti-
inflammatory target. Inhibition of PKC activity repre-
sents one such target as PKC inhibitors have been in
development for many years as potential anti-cancer
therapies, many of which are orally bioavailable [9]. Fur-
thermore the relative redundancy in PKC function due
Figure 5 The downstream effect of PKC β inhibition on
oxidative burst. Cells were pretreated with LY333531 (Ly) at
increasing concentrations and NADPH oxidase activity measured by
DHR fluorescence on flow-cytometry. DPI and Ro-31-8220 (Ro) were
used as positive controls. LY333531 reduced NADPH oxidase activity
at both 100 nM (p<0.01) and 1 μM (p<0.001) consistent with the
concentrations of inhibitor required to reduce NET formation. #
indicates p<0.05, ## indicates p<0.01, and ### indicates p<0.001 vs.
untreated control. ** indicates p<0.01 and *** indicates p<0.001 vs.
PMA treated cells.
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to multiple isoforms may allow the targeting of specific
PKCs in specific cell types at specific organ sites. PKCβ
knock out in a murine model has been demonstrated to
modulate ischemia reperfusion injury in vivo [32], how-
ever these mice may also be immunodeficient [33] and
thus caution must be exercised in any strategy to speci-
fically target PKC. Extracellular traps from both neutro-
phils and mast cells have been demonstrated in psoriatic
skin lesions and from purified neutrophils from psoriasis
patients in association with IL-17 and MPO, directly
implicating extracellular traps in the pathogenesis of dis-
ease [31]. A previous study of a PKC inhibitor AEB071
with specificity for PKC α, β, and θ in psoriasis demon-
strated not only in-vitro effects on T cell proliferation
and cytokine production but also a clinical improvement
in psoriatic lesions in treated patients [34]. We may infer
that some of this effect may be due to a direct effect of
PKC inhibition on NET formation and thus inflamma-
tion in the skin lesions of these patients. Further studies
will of course be required to support this hypothesis.
In summary, NET formation in response to PMA and
DAG analogues is dependent on PKC activation. Further-
more, we demonstrate that conventional PKC and in par-
ticular PKCβ is the predominant isoform responsible for
NET formation under these conditions. Although NETs
have been demonstrated to entrap and kill various micro-
organisms there is burgeoning evidence implicating a role
for these structures in inflammatory disease and potential
modulation of NET production (by PKC inhibition) may
offer a novel anti-inflammatory strategy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RDG, CDL, AM, FL and KM carried out the experiments. RDG, CH, DJD and
AGR designed the experiments and provided a critical review of methods.
RDG drafted the manuscript. All authors read and approved the final
manuscript.
Funding
RDG is a Wellcome Trust Fellow (093767). DD is an MRC Senior Research
Fellow (G1002046). This work was also funded by the Wellcome Trust
(WT094415; CL) and the MRC (G0601481; AGR and CH).
Received: 4 September 2012 Accepted: 22 February 2013
Published: 21 March 2013
References
1. Papayannopoulos V, Staab D, Zychlinsky A: Neutrophil elastase enhances
sputum solubilization in cystic fibrosis patients receiving DNase therapy.
PLoS One 2011, 6:e28526.
2. Nathan C: Neutrophils and immunity: challenges and opportunities. Nat
Rev Immunol 2006, 6:173–182.
3. Brinkmann V, Zychlinsky A: Beneficial suicide: why neutrophils die to
make NETs. Nat Rev Microbiol 2007, 5:577–582.
4. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS,
Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria.
Science 2004, 303:1532–1535.
5. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y,
Brinkmann V, Zychlinsky A: Novel cell death program leads to neutrophil
extracellular traps. J Cell Biol 2007, 176:231–241.
6. Medina E: Neutrophil extracellular traps: a strategic tactic to defeat
pathogens with potential consequences for the host. J Innate Immun
2009, 1:176–180.
7. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, Zychlinsky A, Waldmann
H: Activation of the Raf-MEK-ERK pathway is required for neutrophil
extracellular trap formation. Nat Chem Biol 2011, 7:75–77.
8. Way KJ, Chou E, King GL: Identification of PKC-isoform-specific biological
actions using pharmacological approaches. Trends Pharmacol Sci 2000,
21:181–187.
9. Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ: Protein kinase
C intervention: the state of play. Curr Opin Cell Biol 2009, 21:268–279.
10. Balasubramanian N, Advani SH, Zingde SM: Protein kinase C isoforms in
normal and leukemic neutrophils: altered levels in leukemic neutrophils
and changes during myeloid maturation in chronic myeloid leukemia.
Leuk Res 2002, 26:67–81.
11. Haslett C, Guthrie LA, Kopaniak MM, Johnston RB Jr, Henson PM:
Modulation of multiple neutrophil functions by preparative methods or
trace concentrations of bacterial lipopolysaccharide. Am J Pathol 1985,
119:101–110.
12. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott
A, Martinez-Losa M, Walker TR, Duffin R, et al: Cyclin-dependent kinase
inhibitors enhance the resolution of inflammation by promoting
inflammatory cell apoptosis. Nat Med 2006, 12:1056–1064.
13. Lucas CD, Allen KC, Dorward DA, Hoodless LJ, Melrose LA, Marwick JA,
Tucker CS, Haslett C, Duffin R, Rossi AG: Flavones induce neutrophil
apoptosis by down-regulation of Mcl-1 via a proteasomal-dependent
pathway. FASEB J 2013, 27(3):1084–1094.
14. Metzler KD, Fuchs TA, Nauseef WM, Reumaux D, Roesler J, Schulze I, Wahn
V, Papayannopoulos V, Zychlinsky A: Myeloperoxidase is required for
neutrophil extracellular trap formation: implications for innate immunity.
Blood 2010, 117:953–959.
15. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito
CJ, Singh U, Stramm LE, Melikian-Badalian A, et al: (S)-13-[(dimethylamino)
methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]
pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531)
and related analogues: isozyme selective inhibitors of protein kinase C
beta. J Med Chem 1996, 39:2664–2671.
16. Dekker LV, Leitges M, Altschuler G, Mistry N, McDermott A, Roes J, Segal
AW: Protein kinase C-beta contributes to NADPH oxidase activation in
neutrophils. Biochem J 2000, 347(Pt 1):285–289.
17. Doussiere J, Vignais PV: Diphenylene iodonium as an inhibitor of the
NADPH oxidase complex of bovine neutrophils. Factors controlling the
inhibitory potency of diphenylene iodonium in a cell-free system of
oxidase activation. Eur J Biochem 1992, 208:61–71.
18. Segal AW: How neutrophils kill microbes. Annu Rev Immunol 2005, 23:197–223.
19. Babior BM, Lambeth JD, Nauseef W: The neutrophil NADPH oxidase.
Arch Biochem Biophys 2002, 397:342–344.
20. Yost CC, Cody MJ, Harris ES, Thornton NL, McInturff AM, Martinez ML,
Chandler NB, Rodesch CK, Albertine KH, Petti CA, et al: Impaired neutrophil
extracellular trap (NET) formation: a novel innate immune deficiency of
human neonates. Blood 2009, 113:6419–6427.
21. Urban CF, Reichard U, Brinkmann V, Zychlinsky A: Neutrophil extracellular
traps capture and kill Candida albicans yeast and hyphal forms.
Cell Microbiol 2006, 8:668–676.
22. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A,
Reichenbach J: Restoration of NET formation by gene therapy in CGD
controls aspergillosis. Blood 2009, 114:2619–2622.
23. Ermert D, Urban CF, Laube B, Goosmann C, Zychlinsky A, Brinkmann V:
Mouse neutrophil extracellular traps in microbial infections. J Innate
Immun 2009, 1:181–193.
24. Papayannopoulos V, Zychlinsky A: NETs: a new strategy for using old
weapons. Trends Immunol 2009, 30:513–521.
25. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W,
Brinkmann V, Jungblut PR, Zychlinsky A: Neutrophil extracellular traps
contain calprotectin, a cytosolic protein complex involved in host
defense against Candida albicans. PLoS Pathog 2009,
5:e1000639.
26. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S,
Chamilos G, Sebasigari R, Riccieri V, et al: Neutrophils activate
plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in
systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
Gray et al. Journal of Inflammation 2013, 10:12 Page 7 of 8
http://www.journal-inflammation.com/content/10/1/12
27. Leffler J, Martin M, Gullstrand B, Tyden H, Lood C, Truedsson L, Bengtsson
AA, Blom AM: Neutrophil extracellular traps that are not degraded in
systemic lupus erythematosus activate complement exacerbating the
disease. J Immunol 2012, 188(7):3522–3531.
28. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M,
Baisch J, Guiducci C, Coffman RL, et al: Netting neutrophils are major
inducers of type I IFN production in pediatric systemic lupus
erythematosus. Sci Transl Med 2011, 3:73ra20.
29. Manzenreiter R, Kienberger F, Marcos V, Schilcher K, Krautgartner WD,
Obermayer A, Huml M, Stoiber W, Hector A, Griese M, et al: Ultrastructural
characterization of cystic fibrosis sputum using atomic force and
scanning electron microscopy. J Cyst Fibros 2012, 11(2):84–92.
30. Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer
EM, Krautgartner WD, Stoiber W, Belohradsky BH, et al: CXCR2 mediates
NADPH oxidase-independent neutrophil extracellular trap formation in
cystic fibrosis airway inflammation. Nat Med 2010, 16:1018–1023.
31. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva
EC, Shah P, Kaplan MJ, Bruce AT: Mast cells and neutrophils release IL-17
through extracellular trap formation in psoriasis. J Immunol 2011,
187:490–500.
32. Kong L, Andrassy M, Chang JS, Huang C, Asai T, Szabolcs MJ, Homma S, Liu
R, Zou YS, Leitges M, et al: PKCbeta modulates ischemia-reperfusion injury
in the heart. Am J Physiol Heart Circ Physiol 2008, 294:H1862–H1870.
33. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S,
Tarakhovsky A: Immunodeficiency in protein kinase cbeta-deficient mice.
Science 1996, 273:788–791.
34. Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T,
Kopp T, Fallahi N, Stary G, et al: The PKC inhibitor AEB071 may be a
therapeutic option for psoriasis. J Clin Invest 2008, 118:3151–3159.
doi:10.1186/1476-9255-10-12
Cite this article as: Gray et al.: Activation of conventional protein kinase
C (PKC) is critical in the generation of human neutrophil extracellular
traps. Journal of Inflammation 2013 10:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gray et al. Journal of Inflammation 2013, 10:12 Page 8 of 8
http://www.journal-inflammation.com/content/10/1/12
